330 results
8-K
EX-99.1
LCTX
Lineage Cell Therapeutics Inc
9 May 24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:10pm
with Genentech to Support Ongoing Development of the OpRegen® Program
Long-Term Visual Benefits from a Single Administration with OpRegen Reported … to, statements relating to: the benefits of our new services agreement Genentech and its impact on advancing the OpRegen program; the commencement
8-K
EX-1.1
LCTX
Lineage Cell Therapeutics Inc
22 Mar 24
Entry into a Material Definitive Agreement
4:15pm
(excluding for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using reasonable … units or other awards pursuant to any employee or director stock option or benefits plan, stock ownership plan or dividend reinvestment plan
8-K
EX-99.1
cd72p5y vrtuq0r
9 Nov 23
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.1
jzb2e7f
10 Nov 22
LINEAGE CELL THERAPEUTICS REPORTs THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
4:11pm